Patented biomarker for cardiac injury. 

2020 ESC Guidelines for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation

ESC 2020 Guidelines

In the recently published 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, cMyC is mentioned as the following:
Assay specific cut-off levels in ng/l within the 0h/1h and 0h/2h algorithms.